Quantifying absolute neutralization titers against SARS-CoV-2 by a standardized virus neutralization assay allows for cross-cohort comparisons of COVID-19 sera

Mostrar otras versiones (1)

The global COVID-19 pandemic has mobilized efforts to develop vaccines and antibody-based therapeutics, including convalescent plasma therapy, that inhibit viral entry by inducing or transferring neutralizing antibodies (nAbs) against the SARS-CoV-2 spike glycoprotein (CoV2-S). However, rigorous eff...

Descripción completa

Detalles Bibliográficos
Autores principales: Oguntuyo, Kasopefoluwa Y., Stevens, Christian S., Hung, Chuan-Tien, Ikegame, Satoshi, Acklin, Joshua A., Kowdle, Shreyas S., Carmichael, Jillian C., Chiu, Hsin-Ping, Azarm, Kristopher D., Haas, Griffin D., Amanat, Fatima, Klingler, Jéromine, Baine, Ian, Arinsburg, Suzanne, Bandres, Juan C., Siddiquey, Mohammed N.A., Schilke, Robert M., Woolard, Matthew D., Zhang, Hongbo, Duty, Andrew J., Kraus, Thomas A., Moran, Thomas M., Tortorella, Domenico, Lim, Jean K., Gamarnik, Andrea V., Hioe, Catarina E., Zolla-Pazner, Susan, Ivanov, Stanimir S., Kamil, Jeremy P., Krammer, Florian, Lee, Benhur
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7430605/
https://www.ncbi.nlm.nih.gov/pubmed/32817961
http://dx.doi.org/10.1101/2020.08.13.20157222

Ejemplares similares

Ejemplares similares